61
Drug Models of Cardiac Channelopathies Chu-Pin Lo Department of Financial and Computational Mathematics Providence University, Taiwan (數學年會, 2013.12.7, 中山大學)

Presentation (c.p.lo) 13

Embed Size (px)

Citation preview

Page 1: Presentation (c.p.lo) 13

Drug Models of Cardiac Channelopathies

Chu-Pin Lo

Department of Financial and Computational Mathematics

Providence University, Taiwan

(數學年會, 2013.12.7, 中山大學)

Page 2: Presentation (c.p.lo) 13
Page 3: Presentation (c.p.lo) 13

Proteins involved in inherited arrhythmogenic disorders

Page 4: Presentation (c.p.lo) 13

Outline

Heart Modeling and Computation

Examples of Ion Channelopathies and Drug Models:

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT):

RyR2 Mutations: R4496C, A4860G,…

Casq2 Mutation & Flecainide Effects

Page 5: Presentation (c.p.lo) 13

Heart Modeling and Computation

Page 6: Presentation (c.p.lo) 13

Cell Model

From website

Page 7: Presentation (c.p.lo) 13

Some Ventricle Cell Model:

Guinea-Pig:

Luo-Rudy Series model (Luo 1994,Faber 2007, Gaur 2011)

Dog/Canine:

Winslow (1999), Fox model (2002), Hund-Rudy model (2004)

Rabbit:

Puglisi (2001), Shannon (2004), Mahajan (2008)

Human:

ten Tusscher (,2004, 2006), Grandi (2010), O’Hara (2011)

Page 8: Presentation (c.p.lo) 13

Tissue Structure

Page 9: Presentation (c.p.lo) 13

Heart Structure: Fiber-Sheet

Page 10: Presentation (c.p.lo) 13

),(

),,,(

),(

/),,()(

3

2

1

BSgB

BSYVgS

YVgY

CSYVIVDV

t

t

t

miont

2

321

1

1

of buffers :),,(

ionconcentrat ionic :),...,(

variablesgating :),...,(

potential :

CabbbB

ssS

yyY

V

m

n

Tissue & Whole Heart Model

Page 11: Presentation (c.p.lo) 13

Example

Catecholaminergic Polymorphic

Ventricular Tachycardia (CPVT):

RyR2 Channel Mutations &

Flec Effects (Casq2 Mutation)

Page 12: Presentation (c.p.lo) 13

(From Bers, Nature 2002)

Calcium Handling in Ventricular Myocyte

http://edoc.hu-berlin.de/dissertationen/abdelaziz-ahmed-ihab-2004-09-20/HTML/chapter1.html

Bers 2002

Page 13: Presentation (c.p.lo) 13

RyR2 mutations

(R4496C, A4860G)

Page 14: Presentation (c.p.lo) 13

RyR2 mutation (R4496C)

Page 15: Presentation (c.p.lo) 13

Simulation Model of RyR2

Mutation (R4496C)

Page 16: Presentation (c.p.lo) 13

RyR2 Markov Model

G.M.Faber and Y.Rudy, 2007

Page 17: Presentation (c.p.lo) 13

RyR2 Model for CPVT R4496C

• Enhanced dependence on SR Ca2+ and

subspace Ca2+ concentrations of open

probability

• Reduced SOICR threshold

• Strengthened SOICR

Validated by Experiment Results

Page 18: Presentation (c.p.lo) 13

CPVT RyR2 mutation effect:

Reduced SOICR threshold

D. Jiang et al., PNAS 2004 Nian Liu et al., 2008

Page 19: Presentation (c.p.lo) 13

Therapeutic Targeted Sites of CPVT

Page 20: Presentation (c.p.lo) 13

Blocker for ICa,L ,IUP

Page 21: Presentation (c.p.lo) 13

Simulation Result: Block Effects of ICa,L & IUP

R.J. Sung & C.P.Lo, 2011

Page 22: Presentation (c.p.lo) 13

Simulation Result:Synergistic Block Effect of ICa,L and IUP

R.J. Sung & C.P.Lo, 2011

Page 23: Presentation (c.p.lo) 13

Experiment: ICaL blocker+beta blocker (1)

R. Rosso et al., 2011

Page 24: Presentation (c.p.lo) 13

Experiment: ICaL blocker+beta blocker (2)

R. Rosso et al., 2011

Page 25: Presentation (c.p.lo) 13

RyR2-A4860G mutation (D.Jiang, 2007)

(opposite effects to R4496C)

• diminished response of RyR2 to SR Ca2+

• attenuated SOICR

• causing catecholaminergic idiopathic VF

?? caused by Ca2+, Vm alternans

Page 26: Presentation (c.p.lo) 13

Flecainide Drug Effects

(Casq2 Mutation )

Page 27: Presentation (c.p.lo) 13

Flecainide Effects on CPVT

(RyR2-R4496C, Casq2 -/-)

Nian Liu et al.(2011)

(RyR2-R4496C)

B.C.Knollmann et al. (2009,2010,2011)

(Casq2 -/-)

Page 28: Presentation (c.p.lo) 13

Flecainide Effect on CPVT

Page 29: Presentation (c.p.lo) 13

Flecainide Effect on CPVT

CASQ2

mutation

RyR2

mutation

Page 30: Presentation (c.p.lo) 13

Flecainide Effects on

Individual Ion Channels

• INa: H. Liu et al. (2003), E. Ramos et al. (2004)

• RyR2: B.C.Knollmann et al. (2009,2010,2011)

• IKr: C.Y.Du et al. (2011)

• IK1: R.Caballero et al. (2010)

Page 31: Presentation (c.p.lo) 13

Flecainide Effects on INa

Page 32: Presentation (c.p.lo) 13

Flecainide effects on INa

Page 33: Presentation (c.p.lo) 13

Flec effects on INa: use-dependent

inhibition, resting block, voltage dependent

Page 34: Presentation (c.p.lo) 13

Flec effects on INa:

recovery property

Page 35: Presentation (c.p.lo) 13

Flecainide Effects on RyR2

Page 36: Presentation (c.p.lo) 13

Flecainide Effects on RyR2

Page 37: Presentation (c.p.lo) 13

Flec reduces Ca2+ waves & keeps SR level

Page 38: Presentation (c.p.lo) 13

Flec enhances Ca2+ spark

Page 39: Presentation (c.p.lo) 13

Single RyR2 Channel:

Flec induces bursting & substate

Page 40: Presentation (c.p.lo) 13

Flec effects on bursting parameters

Page 41: Presentation (c.p.lo) 13

Flec on RyR2 is dominant

Page 42: Presentation (c.p.lo) 13

Simulation Results on Flecainide

Drug Effects

Page 43: Presentation (c.p.lo) 13

Drug Effects on INa:

Page 44: Presentation (c.p.lo) 13

INa drug model scheme

Page 45: Presentation (c.p.lo) 13

Flec preferentially bind open state &

simple bimolecular binding

Page 46: Presentation (c.p.lo) 13

Flec does not appeciably interact with the inactivated state

Page 47: Presentation (c.p.lo) 13

Flec interacts with closed state

Page 48: Presentation (c.p.lo) 13

Results:

Resting & Exercise (use-dependent)

Page 49: Presentation (c.p.lo) 13

Results:

Voltage Dependence of Drug Effect

(Proof of Open State Blocker)

Page 50: Presentation (c.p.lo) 13

Results:

Recovery after Drug Treatment

Page 51: Presentation (c.p.lo) 13

Drug Effects on RyR2:

(Casq2-/- Case)

Page 52: Presentation (c.p.lo) 13

Model for SR Ca2+ Handling

(subcellular, stochastic local control)

Page 53: Presentation (c.p.lo) 13

Model for SR Ca2+ Handling

Page 54: Presentation (c.p.lo) 13

SR Structure

Jana M. Hartman (2010)

Page 55: Presentation (c.p.lo) 13

Flec enhances Ca2+ spark

Page 56: Presentation (c.p.lo) 13

Flec reduces Ca2+ wave

Page 57: Presentation (c.p.lo) 13

Flec Keep SR Ca2+ level

Page 58: Presentation (c.p.lo) 13

Flec induces substate

(single channel trace)

Page 59: Presentation (c.p.lo) 13

Flec effecs on DAD, TA

Page 60: Presentation (c.p.lo) 13

Conclusion

• validated CPVT RyR2-R4496C model

• validated flecainide state-dependent models

on INa and RyR2 (Casq2 -/-)

Page 61: Presentation (c.p.lo) 13

Thanks for your

Attention !